サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1279870

CAR T細胞療法の世界市場規模調査＆予測、適応症別、薬剤タイプ別、エンドユーザー別、地域別分析、2023-2030年

Global CAR T-Cell therapy Market Size study & Forecast, by Indication, By Drug Type, By End user, and Regional Analysis, 2023-2030
出版日: | 発行: Bizwit Research & Consulting LLP | ページ情報: 英文 | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
CAR T細胞療法の世界市場規模調査＆予測、適応症別、薬剤タイプ別、エンドユーザー別、地域別分析、2023-2030年
出版日: 2023年05月20日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のCAR T細胞療法市場は、2022年に約19億3,000万米ドルと評価され、予測期間2023-2030年には13.5%以上の健全な成長率で成長すると予測されています。

キメラ抗原受容体（CAR）T細胞療法は、新しい形態のがん治療で、医療専門家が研究室でT細胞を改変してからがん患者の体内に注入し、がん細胞を検出して排除できるようにするものです。CAR T細胞療法によって、免疫システムは悪性細胞を認識するように訓練されます。CAR T細胞療法により、悪性細胞に対する免疫応答が促進されます。CAR T細胞療法の市場は、主に、がん治療に適した治療薬に対する需要の増加、一部の国におけるCAR T細胞療法薬に対する有利な償還政策、CAR T細胞療法薬に対する消費者の認知度の向上によって牽引されています。さらに、最近のCAR-T細胞療法の商業化と臨床試験活動の急増が、市場拡大にさらなる影響を及ぼしています。

さらに、白血病やリンパ腫などのガンの発生率の増加が、CAR T細胞療法の需要を直接的に増大させています。世界保健機関（WHO）によると、2020年の白血病のがん患者数は47万5,000人と推定され、2040年には69万2,000人に達すると予測されています。したがって、がんの有病率の増加は、幅広い診断と治療の選択肢に対する需要を促進し、それがCAR T細胞療法市場の成長を加速させています。さらに、研究開発への投資の増加や技術の進歩は、予測期間中にさまざまな有利な機会をもたらします。しかし、熟練した専門家の不足とCAR T細胞療法の開発コストの高さが、2023年から2030年の予測期間を通じて市場の成長に課題しています。

CAR T細胞療法の世界市場調査において考慮された主要地域は、アジア太平洋、北米、欧州、ラテンアメリカ、中東・アフリカです。北米は、規制当局の認可の増加、新興国市場への投資の増加、技術開発の進展により、2022年の市場を独占しました。一方、アジア太平洋は予測期間中、最も高いCAGRで成長すると予想されています。がんの有病率の上昇、政府機関による新規治療薬の研究資金の増加、新規治療薬の認知度の向上と承認の増加が、この地域全体の市場需要を大きく後押ししています。

本調査の目的は、近年におけるさまざまなセグメントと国の市場規模を定義し、今後数年間の値を予測することです。本レポートは、調査対象国の産業の質的・量的な側面を取り入れるよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題など、重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢や製品提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場での潜在的な機会も組み込んでいます。.

目次

第1章 エグゼクティブサマリー

  • マーケットスナップショット
  • 世界市場・セグメント別市場推計・予測、2020年～2030年
    • CAR T細胞療法市場：地域別、2020-2030年
    • CAR T細胞療法市場：適応症別、2020-2030年
    • CAR T細胞療法市場、薬剤タイプ別、2020-2030年
    • CAR T細胞療法市場：エンドユーザー別、2020年～2030年
  • 主な動向
  • 調査手法
  • 調査の前提条件

第2章 CAR T細胞療法の世界市場の定義と範囲

  • 調査目的
  • 市場の定義と範囲
    • 産業の進化
    • 本調査の対象範囲
  • 本調査の対象年
  • 通貨換算レート

第3章 CAR T細胞療法の世界市場力学

  • CAR T細胞療法市場の影響分析（2020年～2030年）
    • 市場促進要因
      • 白血病やリンパ腫などのがんの発生率の増加
      • CAR T細胞療法治療薬に対する有利な償還政策
    • 市場の課題
      • 熟練した専門家の不足
      • CAR T細胞療法の開発コストの高さ
    • 市場機会
      • 研究開発への投資拡大
      • 技術的進歩の増加

第4章 世界のCAR T細胞療法市場産業分析

  • ポーターの5フォースモデル
    • 供給企業の交渉力
    • 買い手の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係
  • ポーターの5フォース影響分析
  • PEST分析
    • 政治的
    • 経済的
    • 社会的
    • 技術的
    • 環境
    • 法律
  • トップ投資機会
  • 主要成功戦略
  • COVID-19影響度分析
  • 破壊的動向
  • 業界専門家の視点
  • アナリストの提言と結論

第5章 CAR T細胞療法の世界市場：適応症別

  • 市場スナップショット
  • CAR T細胞療法の世界市場：適応症別、実績、潜在能力分析
  • CAR T細胞療法の世界市場、適応症別推定・予測2020-2030
  • CAR T細胞療法の世界市場、サブセグメント別分析
    • リンパ腫
    • 急性リンパ球性白血病
    • その他

第6章 CAR T細胞療法の世界市場：薬剤タイプ別

  • 市場スナップショット
  • CAR T細胞療法の世界市場：薬剤タイプ別、実績 - ポテンシャル分析
  • CAR T細胞療法の世界市場、薬剤タイプ別推定・予測2020-2030
  • CAR T細胞療法の世界市場、サブセグメント別分析
    • アクシキャブタジェン・シロロイセル
    • ティサゲンレキュール
    • ブレクスカブタジェンオートルーセル
    • その他

第7章 CAR T細胞療法の世界市場：エンドユーザー別

  • 市場スナップショット
  • CAR T細胞療法の世界市場：エンドユーザー別、業績-潜在能力分析
  • CAR細胞療法の世界市場、エンドユーザー別推定・予測2020～2030年
  • CAR T細胞療法の世界市場、サブセグメント別分析
    • 病院
    • がん治療センター

第8章 CAR T細胞療法の世界市場：地域別分析

  • 上位の主要国
  • 主要な新興国
  • CAR T細胞療法市場、地域別市場スナップショット
  • 北米
    • 米国
      • 適応症別の推定・予測、2020-2030年
      • 薬剤タイプ別の推定・予測、2020-2030年
      • エンドユーザー別の推定・予測、2020-2030年
    • カナダ
  • 欧州CAR T細胞療法市場スナップショット
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • アジア太平洋地域のCAR T細胞療法市場スナップショット
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカのCAR T細胞療法市場スナップショット
    • ブラジル
    • メキシコ
  • 中東・アフリカ地域
    • サウジアラビア
    • 南アフリカ
    • その他中東とアフリカ

第9章 競合情報

  • 主要企業のSWOT分析
    • 企業1
    • 企業2
    • 企業3
  • 主要市場戦略
  • 企業プロファイル
    • Autolus Therapeutics
      • 主要情報
      • 概要
      • 財務情報（データの入手が可能な場合のみ）
      • 製品概要
      • 最近の動向
    • Bluebird bio, Inc.
    • Bristol-Myers Squibb
    • Caribou Biosciences, Inc.
    • Cartesian Therapeutics, Inc.
    • Celgene Corporation
    • Gilead Sciences, Inc.（Kite Pharma Inc.）
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer, Inc.

第10章 調査プロセス

  • 調査プロセス
    • データマイニング
    • 分析
    • 市場推定
    • バリデーション
    • 出版
  • 調査の特徴
  • 調査の前提条件
図表

LIST OF TABLES

  • TABLE 1. Global CAR T-Cell therapy Market, report scope
  • TABLE 2. Global CAR T-Cell therapy Market estimates & forecasts by Region 2020-2030 (USD Billion)
  • TABLE 3. Global CAR T-Cell therapy Market estimates & forecasts by Indication 2020-2030 (USD Billion)
  • TABLE 4. Global CAR T-Cell therapy Market estimates & forecasts by Drug type 2020-2030 (USD Billion)
  • TABLE 5. Global CAR T-Cell therapy Market estimates & forecasts by End user 2020-2030 (USD Billion)
  • TABLE 6. Global CAR T-Cell therapy Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 7. Global CAR T-Cell therapy Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 8. Global CAR T-Cell therapy Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 9. Global CAR T-Cell therapy Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 10. Global CAR T-Cell therapy Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 11. Global CAR T-Cell therapy Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 12. Global CAR T-Cell therapy Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 13. Global CAR T-Cell therapy Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 14. Global CAR T-Cell therapy Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 15. Global CAR T-Cell therapy Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 16. U.S. CAR T-Cell therapy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 17. U.S. CAR T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 18. U.S. CAR T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 19. Canada CAR T-Cell therapy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 20. Canada CAR T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 21. Canada CAR T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 22. UK CAR T-Cell therapy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 23. UK CAR T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 24. UK CAR T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 25. Germany CAR T-Cell therapy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 26. Germany CAR T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 27. Germany CAR T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 28. France CAR T-Cell therapy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 29. France CAR T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 30. France CAR T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 31. Italy CAR T-Cell therapy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 32. Italy CAR T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 33. Italy CAR T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 34. Spain CAR T-Cell therapy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 35. Spain CAR T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 36. Spain CAR T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 37. RoE CAR T-Cell therapy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 38. RoE CAR T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 39. RoE CAR T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 40. China CAR T-Cell therapy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 41. China CAR T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 42. China CAR T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 43. India CAR T-Cell therapy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 44. India CAR T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 45. India CAR T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 46. Japan CAR T-Cell therapy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 47. Japan CAR T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 48. Japan CAR T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 49. South Korea CAR T-Cell therapy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 50. South Korea CAR T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 51. South Korea CAR T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 52. Australia CAR T-Cell therapy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 53. Australia CAR T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 54. Australia CAR T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 55. RoAPAC CAR T-Cell therapy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 56. RoAPAC CAR T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 57. RoAPAC CAR T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 58. Brazil CAR T-Cell therapy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 59. Brazil CAR T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 60. Brazil CAR T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 61. Mexico CAR T-Cell therapy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 62. Mexico CAR T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 63. Mexico CAR T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 64. RoLA CAR T-Cell therapy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 65. RoLA CAR T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 66. RoLA CAR T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 67. Saudi Arabia CAR T-Cell therapy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 68. South Africa CAR T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 69. RoMEA CAR T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 70. List of secondary sources, used in the study of global CAR T-Cell therapy Market
  • TABLE 71. List of primary sources, used in the study of global CAR T-Cell therapy Market
  • TABLE 72. Years considered for the study
  • TABLE 73. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global CAR T-Cell therapy Market, research methodology
  • FIG 2. Global CAR T-Cell therapy Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global CAR T-Cell therapy Market, key trends 2022
  • FIG 5. Global CAR T-Cell therapy Market, growth prospects 2023-2030
  • FIG 6. Global CAR T-Cell therapy Market, porters 5 force model
  • FIG 7. Global CAR T-Cell therapy Market, pest analysis
  • FIG 8. Global CAR T-Cell therapy Market, value chain analysis
  • FIG 9. Global CAR T-Cell therapy Market by segment, 2020 & 2030 (USD Billion)
  • FIG 10. Global CAR T-Cell therapy Market by segment, 2020 & 2030 (USD Billion)
  • FIG 11. Global CAR T-Cell therapy Market by segment, 2020 & 2030 (USD Billion)
  • FIG 12. Global CAR T-Cell therapy Market by segment, 2020 & 2030 (USD Billion)
  • FIG 13. Global CAR T-Cell therapy Market by segment, 2020 & 2030 (USD Billion)
  • FIG 14. Global CAR T-Cell therapy Market, regional snapshot 2020 & 2030
  • FIG 15. North America CAR T-Cell therapy Market 2020 & 2030 (USD Billion)
  • FIG 16. Europe CAR T-Cell therapy Market 2020 & 2030 (USD Billion)
  • FIG 17. Asia pacific CAR T-Cell therapy Market 2020 & 2030 (USD Billion)
  • FIG 18. Latin America CAR T-Cell therapy Market 2020 & 2030 (USD Billion)
  • FIG 19. Middle East & Africa CAR T-Cell therapy Market 2020 & 2030 (USD Billion)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

目次

Global CAR T-Cell therapy Market is valued at approximately USD 1.93 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 13.5% over the forecast period 2023-2030. Chimeric antigen receptor (CAR) T cell therapy is a novel form of cancer therapy in which medical experts modify T cells in a lab before injecting them into cancer patients' bodies to enable them to detect and eliminate cancer cells. The immune system is trained to recognize malignant cells by CAR T-cell therapy. The immune response against malignant cells is boosted by CAR T-cell treatment. The market for CAR T-cell therapy is primarily driven by an increase in the demand for suitable therapeutics for the treatment of cancer, favorable reimbursement policies for CAR T-cell therapy medications in some countries, and an increase in consumer awareness of CAR T-cell therapy medications. Additionally, the recent commercialization of CAR-T cell therapy and the surging clinical trial activities are further influencing the market expansion.

In addition, an increase in the incidence of cancer such as leukemia and lymphoma are directly augmenting the demand for CAR T-Cell therapy. According to World Health Organization (WHO), in 2020, the number of leukemia cancer cases is estimated to account for 475 thousand, which is projected to reach 692 thousand patients by the year 2040. Accordingly, the growing prevalence of cancer is fueling the demand for a wide range of diagnosis and treatment alternatives, which, in turn, accelerates the growth of the CAR T-Cell therapy Market. Moreover, the growing investment in research and development, as well as increasing advancements in technology present various lucrative opportunities over the forecasting years. However, the unavailability of skilled professionals and the high cost of developing CAR T-cell therapy are challenging the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global CAR T-Cell therapy Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the increasing regulatory approvals, growing investment in advancing healthcare facilities, and rising technological developments. Whereas, Asia Pacific is expected to grow at the highest CAGR over the forecasting years. The rising prevalence of cancer, increasing research funding for novel therapeutics by government bodies, and growing awareness and increase in approval of novel medications are significantly propelling the market demand across the region.

Major market players included in this report are:

  • Autolus Therapeutics
  • Bluebird bio, Inc.
  • Bristol-Myers Squibb
  • Caribou Biosciences, Inc.
  • Cartesian Therapeutics, Inc.
  • Celgene Corporation
  • Gilead Sciences, Inc. (Kite Pharma Inc.)
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.

Recent Developments in the Market:

  • In June 2022, Bristol-Myers Squibb Company announced that the company received the U.S. Food and Drug Administration (FDA) approval for Breyanzi CAR T cell therapy to cure refractory or relapsed large B-cell lymphoma after one prior therapy. The Phase 2 pilot company-sponsored research of a CAR T cell treatment in patients with primary refractory or relapsed LBCL served as the foundation for the approval.
  • In February 2022, Johnson & Johnson Services, Inc. declared that the U.S. Food and Drug Administration had approved CARVYKTI (ciltacabtagene autoleucel), a BCMA-Directed CAR-T Immunotherapy for the treatment of Patients with Relapsed or Refractory Multiple Myeloma.

Global CAR T-Cell therapy Market Report Scope:

  • Historical Data: - 2020 - 2021
  • Base Year for Estimation: - 2022
  • Forecast period: - 2023-2030
  • Report Coverage: - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: - Indication, Drug type, End user, Region
  • Regional Scope: - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope: - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Indication:

  • Lymphoma
  • Acute Lymphocytic Leukemia
  • Others

By Drug type:

  • Axicabtagene Ciloleucel
  • Tisagenlecleucel
  • Brexucabtagene Autoleucel
  • Others

By End-user:

  • Hospitals
  • Cancer Treatment Centers

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
    • 1.2.1. CAR T-Cell therapy Market, by Region, 2020-2030 (USD Billion)
    • 1.2.2. CAR T-Cell therapy Market, by Indication, 2020-2030 (USD Billion)
    • 1.2.3. CAR T-Cell therapy Market, by Drug type, 2020-2030 (USD Billion)
    • 1.2.4. CAR T-Cell therapy Market, by End user, 2020-2030 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global CAR T-Cell therapy Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Industry Evolution
    • 2.2.2. Scope of the Study
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global CAR T-Cell therapy Market Dynamics

  • 3.1. CAR T-Cell therapy Market Impact Analysis (2020-2030)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increase in the incidence of cancer such as leukemia and lymphoma
      • 3.1.1.2. Favorable reimbursement policies for CAR T-cell therapy medications
    • 3.1.2. Market Challenges
      • 3.1.2.1. Unavailability of skilled professionals
      • 3.1.2.2. High cost of developing CAR T-cell therapy
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Growing investment in research and development
      • 3.1.3.2. Increasing advancements in technology

Chapter 4. Global CAR T-Cell therapy Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Porter's 5 Force Impact Analysis
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
    • 4.3.5. Environmental
    • 4.3.6. Legal
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. COVID-19 Impact Analysis
  • 4.7. Disruptive Trends
  • 4.8. Industry Expert Perspective
  • 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global CAR T-Cell therapy Market, by Indication

  • 5.1. Market Snapshot
  • 5.2. Global CAR T-Cell therapy Market by Indication, Performance - Potential Analysis
  • 5.3. Global CAR T-Cell therapy Market Estimates & Forecasts by Indication 2020-2030 (USD Billion)
  • 5.4. CAR T-Cell therapy Market, Sub Segment Analysis
    • 5.4.1. Lymphoma
    • 5.4.2. Acute Lymphocytic Leukemia
    • 5.4.3. Others

Chapter 6. Global CAR T-Cell therapy Market, by Drug type

  • 6.1. Market Snapshot
  • 6.2. Global CAR T-Cell therapy Market by Drug type, Performance - Potential Analysis
  • 6.3. Global CAR T-Cell therapy Market Estimates & Forecasts by Drug type 2020-2030 (USD Billion)
  • 6.4. CAR T-Cell therapy Market, Sub Segment Analysis
    • 6.4.1. Axicabtagene Ciloleucel
    • 6.4.2. Tisagenlecleucel
    • 6.4.3. Brexucabtagene Autoleucel
    • 6.4.4. Others

Chapter 7. Global CAR T-Cell therapy Market, by End user

  • 7.1. Market Snapshot
  • 7.2. Global CAR T-Cell therapy Market by End user, Performance - Potential Analysis
  • 7.3. Global CAR T-Cell therapy Market Estimates & Forecasts by End user 2020-2030 (USD Billion)
  • 7.4. CAR T-Cell therapy Market, Sub Segment Analysis
    • 7.4.1. Hospitals
    • 7.4.2. Cancer Treatment Centers

Chapter 8. Global CAR T-Cell therapy Market, Regional Analysis

  • 8.1. Top Leading Countries
  • 8.2. Top Emerging Countries
  • 8.3. CAR T-Cell therapy Market, Regional Market Snapshot
  • 8.4. North America CAR T-Cell therapy Market
    • 8.4.1. U.S. CAR T-Cell therapy Market
      • 8.4.1.1. Indication breakdown estimates & forecasts, 2020-2030
      • 8.4.1.2. Drug type breakdown estimates & forecasts, 2020-2030
      • 8.4.1.3. End user breakdown estimates & forecasts, 2020-2030
    • 8.4.2. Canada CAR T-Cell therapy Market
  • 8.5. Europe CAR T-Cell therapy Market Snapshot
    • 8.5.1. U.K. CAR T-Cell therapy Market
    • 8.5.2. Germany CAR T-Cell therapy Market
    • 8.5.3. France CAR T-Cell therapy Market
    • 8.5.4. Spain CAR T-Cell therapy Market
    • 8.5.5. Italy CAR T-Cell therapy Market
    • 8.5.6. Rest of Europe CAR T-Cell therapy Market
  • 8.6. Asia-Pacific CAR T-Cell therapy Market Snapshot
    • 8.6.1. China CAR T-Cell therapy Market
    • 8.6.2. India CAR T-Cell therapy Market
    • 8.6.3. Japan CAR T-Cell therapy Market
    • 8.6.4. Australia CAR T-Cell therapy Market
    • 8.6.5. South Korea CAR T-Cell therapy Market
    • 8.6.6. Rest of Asia Pacific CAR T-Cell therapy Market
  • 8.7. Latin America CAR T-Cell therapy Market Snapshot
    • 8.7.1. Brazil CAR T-Cell therapy Market
    • 8.7.2. Mexico CAR T-Cell therapy Market
  • 8.8. Middle East & Africa CAR T-Cell therapy Market
    • 8.8.1. Saudi Arabia CAR T-Cell therapy Market
    • 8.8.2. South Africa CAR T-Cell therapy Market
    • 8.8.3. Rest of Middle East & Africa CAR T-Cell therapy Market

Chapter 9. Competitive Intelligence

  • 9.1. Key Company SWOT Analysis
    • 9.1.1. Company 1
    • 9.1.2. Company 2
    • 9.1.3. Company 3
  • 9.2. Top Market Strategies
  • 9.3. Company Profiles
    • 9.3.1. Autolus Therapeutics
      • 9.3.1.1. Key Information
      • 9.3.1.2. Overview
      • 9.3.1.3. Financial (Subject to Data Availability)
      • 9.3.1.4. Product Summary
      • 9.3.1.5. Recent Developments
    • 9.3.2. Bluebird bio, Inc.
    • 9.3.3. Bristol-Myers Squibb
    • 9.3.4. Caribou Biosciences, Inc.
    • 9.3.5. Cartesian Therapeutics, Inc.
    • 9.3.6. Celgene Corporation
    • 9.3.7. Gilead Sciences, Inc. (Kite Pharma Inc.)
    • 9.3.8. Merck & Co., Inc.
    • 9.3.9. Novartis AG
    • 9.3.10. Pfizer, Inc.

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption